<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Teva Reports Q1:15 Updates Pipeline and Provides Insight on SD-809</title>
	<pubDate>2015-04-30T16:28:47+02:00</pubDate>
	<wp:post_id>6186</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results for the quarter, the group presented an update of its specialty pipeline.<wbr> Interestingly, the chart did not provide new information on the status of Albtropin (Ph2/<wbr>GHD), Laquinimod and Pridopidine (Ph2 for HD).<wbr> Regarding SD-809 management outlined favorable side effect profile of the BID dosing, and outcomes from a physician survey which indicate market opportunities with significant commercial potential forfor HD; TD, and Tourette Syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7996_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7996_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7996_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology7996attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7996_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7996_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(82,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7996_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7996">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-30T16:28:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-30T16:28:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Lexicon Q1:15 Results</title>
	<pubDate>2015-04-30T14:18:47+02:00</pubDate>
	<wp:post_id>6187</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon’s revenues increased to $1.<wbr>8M (from $0.<wbr>3M in Q1:14).<wbr> R&amp;D expenses decreased 13% due to reductions in personnel costs.<wbr> Next strategic milestones will be the announcement of top-line data from the TELESTAR trial in Q3.<wbr> It was reported that TELECAST enrollment is to complete on April 30th 2015.<wbr> TELECAST is a supportive study designed to bolster the safety database.<wbr> Below are selected messages from the Q&amp;A session withinvestors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Regarding the TELECAST trial, management pointed out that " <EM>.<wbr>.<wbr>.<wbr> <SPAN id="107" style="BACKGROUND-COLOR: rgb(255,255,0)"></SPAN>CAST is really a supportive study designed to bolster our safety database so that's the primary purpose of that study.<wbr> The <SPAN id="108" style="BACKGROUND-COLOR: rgb(255,255,0)"></SPAN>STAR is the study that is going to provide us with efficiency of efficacy and that's, those, are the top-line results that I think we should be focused on".<wbr></EM> </div><div style="margin-bottom: 10px;">and added " .<wbr>.<wbr>.<wbr> <EM>we expect to have the data in a timely fashion to keep our timelines on the NDA filing so it is a supportive study but we expect to have the data -- we won't have the top-line data at the same time that we have the top-line data from the pivotal study but we will have it in a timely manner to support the NDA filing".<wbr></EM> </div><div style="margin-bottom: 10px;">One question from investor was on the powering assumptions for the Ph3 trial.<wbr> </div><div style="margin-bottom: 10px;">Pablo Lapuerta said <SPAN style="FONT-STYLE: italic">" .<wbr>.<wbr>.<wbr> In our Phase 3 program for TELESTAR the primary endpoint is the reduction in bowel movement frequency averaged over the course of the 12 weeks of the study and the specific reduction in frequency that we're powered for is on the order of one bowel movement per day from a baseline that we expect to range somewhere between approximately five and six.<wbr><BR><BR>However, the powering is done in order to give us the best chance to show robust efficacy.<wbr> So our expectation is based on Phase 2 experience where we showed reductions in bowel movement frequency on the order of 40% in our open label study and on the order of 25% in our short-term placebo-controlled study.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-STYLE: italic">So the -- we powered for a robust program, our expectation is that Phase 3 results should look like Phase 2.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-STYLE: italic">A clinically meaningful change for an individual with this condition would be a reduction in bowel movement frequency of approximately 25% to 30%.<wbr> So that would be a reduction from, say, six bowel movements a day to 4.<wbr>5 or four.<wbr> For a mean change in a clinical trial, the mean change may be a little bit less because there are some responders on Telotristat Etiprate and responders on placebo.<wbr><BR><BR>So we suggest that when the results come out you look for both the mean change in the population overall but also the proportion of patients with at least a 30% reduction in bowel movement frequency from baseline to Week 12 under two different treatment groups.<wbr>"</SPAN> </div><div><SPAN style="FONT-STYLE: italic">Source: Lexcion Transcript</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8040">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-30T14:18:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-30T14:18:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Project for Critical Pharm.'s CriticalSorb Nasal Technology</title>
	<pubDate>2015-04-30T14:02:17+02:00</pubDate>
	<wp:post_id>6188</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Critical Pharm.<wbr>, The U.<wbr> of Nottingham and Nottingham U.<wbr> Hospitals NHS Trust have announced the start of the first Ph1 clinical trial in healthy post-menopausal women of a nano-enabled intransal teriparatide product for the treatment of osteoporosis.<wbr> CriticalSorb has been developed by Critical Pharmaceuticals to improve the absorption of drugs through the nose into the blood stream in the hope that it will replace injections.<wbr> The company has completed two Ph1 with intranasal hGH that have shown comparable activity to injection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The project is using Critical Pharmaceuticals CriticalSorb™ technology to develop a nano-enabled nasal spray formulation of teriparatide that is easy for patients to take and improves efficacy providing optimal drug levels in the body.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Design</U> </div><div style="margin-bottom: 10px;">Five-way cross-over study design in healthy post-menopausal women representative of the target patient population.<wbr> </div><div style="margin-bottom: 10px;"><U>Objectives</U> </div><div style="margin-bottom: 10px;">- to understand the levels of the drug in the body (pharmacokinetics) after intranasal administration of three doses of the teriparatide product versus subcutaneous injection of marketed product.<wbr> </div><div style="margin-bottom: 10px;">The study will also test the performance of two different nasal delivery devices and use scintigraphic imaging to better understand how deposition can influence the levels of drug in the body over time.<wbr> </div><div style="margin-bottom: 10px;"><U>Reference</U> </div><div style="margin-bottom: 10px;">NCT01913834 </div><div>Source: Critical Pharm.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8038">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-30T14:02:17+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-30T14:02:17+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeaways from Valeant Q1:15 Results</title>
	<pubDate>2015-04-30T13:47:28+02:00</pubDate>
	<wp:post_id>6189</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results, company outlined that Salix and Dendreon integrations are largely complete.<wbr> Management said that opportunities for Provenge will probably be to look for a partner in Western EU, and to focus its efforts on the US market.<wbr> Most of the Salix R&amp;D programs will be continued, and this will be updated in Q2.<wbr> Plan to cover primary care through specialty sales force coupled with extensive DTC advertising once IBS-D indication is approved (PDUFA date of May 28; discussion with the FDA on labeling).<wbr> Sales of Xenazine, Top6 products, increased to $57M (vs $50M in Q1:14).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Salix is expected to generate about $1 billion in revenue for Valeant over the final three quarters of 2015.<wbr> That estimate does not include revenue that may come from Salix receiving regulatory approval to market its best-selling drug Xifaxan as a treatment for irritable bowel syndrome.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10449_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Xenazine</STRONG> continues to generate growth.<wbr> Management reported: " .<wbr>.<wbr>.<wbr> we thought we'd see a generic midway through this year.<wbr> Right now our guidance continues to assume that we will have a generic midway through this year.<wbr> That being said, it's not 100% clear that one will be coming out, so that could be upside if it doesn't".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Provenge</STRONG> -  </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10449_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10449_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10449_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10449_5_ScreenCapture5.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10449">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-30T13:47:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-30T13:47:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Q1 Results Reflect Strong Start for 2015</title>
	<pubDate>2015-04-30T12:35:56+02:00</pubDate>
	<wp:post_id>6190</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Group sales reached €12.<wbr>1bn (+14.<wbr>8%, Fx &amp; portfolio adj.<wbr> +2.<wbr>7%) All divisions in HealthCare generated strong growth, with an increase for the pharma segment of 15% (Fx &amp; portfolio adj.<wbr> +7.<wbr>2%).<wbr> Sales growth at Pharmaceuticals was mainly driven by the persistently dynamic sales growth of recently launched products (Xarelto, Eylea, Stivarga, Xofigo, Adempas) which contributed €898M in the quarter.<wbr> Xofigo now ranks 13th position in the Best Selling Pharma Products' list, with sales of €54M (+50%, Fx &amp; portfolio adj.<wbr>+28%).<wbr> Pharma grew in all regions on a currency-adjusted basis, especially in Europe and North America.<wbr> Management Report (Economic Outlook section) indicates that "the pharmaceuticals market is likely to grow rather more slowly in 2015 than in the previous year, especially because of the slightly lower growth rate predicted for this market in the United States.<wbr> Following double-digit growth in the u.<wbr>s.<wbr> last year, which was driven by new product introductions and health system reforms, this market will probably expand at a somewhat slower rate in 2015, partly as a result of patent expirations and launches of new generic products.<wbr> We expect demand to be stable in the emerging economies".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sales of the Pharmaceuticals segment rose by 7.<wbr>2% (Fx &amp; portfolio adj.<wbr>) to €3,200M in Q1:15.<wbr> </div><div style="margin-bottom: 10px;">Xarelto™, Eylea™, Stivarga™, Xofigo™ and Adempas™ posted combined sales of €898M (Q1:14 €598M).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="oncology10447attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(31,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(13,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(25,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10447_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(25,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10447">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-30T12:35:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-30T12:35:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Launch of Autoject Micro - A New Injection Device For Self-Administration</title>
	<pubDate>2015-04-29T15:57:40+02:00</pubDate>
	<wp:post_id>6191</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Owen Mumford unveiled a new addition to its range of automatic 
disposable injection devices at a recent CPHI event in Paris.<wbr> 
With the introduction of the Autoject Micro, the company expands its 
range of automatic injection devices for the self-administration of parenteral 
drugs.<wbr> </div><div style="margin-bottom: 10px;">The Autoject Micro is a new disposable auto-injector that features a patented 
drive mechanism technology that enables auto-injection in a discreet 
package.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11158_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Owen Mumford business development manager George I'ons claims in the press 
release that: "Autoject Micro has been developed to make it easier for patients 
and healthcare professionals to deliver single dose injectable treatments, while 
also addressing cold store and logistics costs with its smaller form 
factor.<wbr>" </div><div style="margin-bottom: 10px;">"Its intuitive design and safety features have been created to address key 
patient concerns such as needlestick anxiety and adherence, while providing 
advanced drug delivery capabilities.<wbr> </div><div style="margin-bottom: 10px;">"It can be supplied fully assembled with a prefilled syringe or in two parts 
ready for final assembly.<wbr>" </div><div style="margin-bottom: 10px;">Key Features </div><div style="margin-bottom: 10px;"><UL><LI>True auto-injection: needle is inserted and dose delivered at the touch of 
  a button</LI>
<LI>Concealed needle to reduce injection anxiety</LI>
<LI>Sharps Injury Prevention: needle is hidden before and after use </LI>
<LI>Protective cap and locking mechanism prevent accidental activation</LI>
<LI>Activation button appears when device is unlocked and ready to use</LI>
<LI>Audible and visual feedback at start and end of dose</LI>
<LI>Convenient size for storage and portability</LI>
<LI>Intuitive: use as a press-button or contact-activated device</LI>
<LI>Large viewing window for easy viewing of syringe</LI>
<LI>Ergonomic: oval shape and large grip detail on cap</LI>
</UL> </div><div>Source: <A href="http://www.omdevicesolutions.com/self-injection-devices/autoinjectors/#autojectmicro">http:/<wbr>/<wbr>www.<wbr>omdevicesolutions.<wbr>com/<wbr>self-injection-devices/<wbr>autoinjectors/<wbr>#autojectmicro</A> </div><!-- Comment details --><a name="pharmaworld11158attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11158_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150431&edate=20150401&rec=11158">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-29T15:57:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-29T15:57:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Pfizer Q1 Results</title>
	<pubDate>2015-04-29T15:13:03+02:00</pubDate>
	<wp:post_id>6192</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results, Chairman and CEO outlined that prime driver of business development is 'to create shareolders value'.<wbr> Being asked on a potential break up of the company (earliest timelines previously reported to occur in 2017), he added that "if a split or getting bigger and then splitting makes sense, we will execute that".<wbr> The acquisition of Hospira has been reported to1/<wbr> be an excellent strategic fit in an attractive and growing market segment, including sterile injectables and biosimilars, and 2/<wbr>accelerate the growth trajectory of the GEP business.<wbr><A class="link" id="L66"> </A>The organization have 88 programs in clinical development with 30 programs in late stage development for registration as of today.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10442_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>LOEs, lost alliance revenues and Lipitor in developed markets <STRONG>negatively</STRONG> impacted revenues of the GEP segment by $667M (11%, operationally).<wbr> All other GEP revenues grew 2% operationally, led by strong growth in emerging markets.<wbr> </LI>
<LI>Global Vaccines Oncology and Consumer Healthcare (VOC) revenues increased by 29% operationally, primarily driven by continued strong Prevnar13 uptake, as well as the US launches of Ibrance (palbociclib) and Nexium 24HR.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
 </div><div style="margin-bottom: 10px;"><P>- Albert Bourla- <SPAN style="FONT-STYLE: italic">President of Vaccines, Oncology &amp; Consumer Healthcare : </SPAN>"Ibrance has been well-received by oncologists.<wbr><A class="link" id="L208"> We have over 800 healthcare practitioners prescribing.<wbr></A> We have over 2,000 new patients in one quarter.<wbr> And we had approximately 3,000 total scripts written so far"</P>
 </div><div style="margin-bottom: 10px;"><P>- CEO outlined that " .<wbr>.<wbr>.<wbr> we will be filing in the EU in the second half of this year"</P></BLOCKQUOTE></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL dir="ltr"><LI>Growth of the Global Innovative Pharmaceutical (GIP) was driven by Lyrica (US and Japan), Eliquis (globally), and Xeljanz (US).<wbr> </LI>
</UL> </div><div>Source: Pfizer Call /<wbr> Transcript </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10524c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Although Pfizer's management intends to effectuate or start the split in <SPAN id="102" style="background-color: #ffffff;">2017</SPAN>, which probably means to take a decision in the latter part of 2016,  analysts see a potential announcement in 2015/<wbr>2016.<wbr> </div><div style="margin-bottom: 10px;">In comparison, </div><div><UL><LI>AbbVie spin-off from Abbott Laboratories was announced over 14 months before the deal was effective
</LI>
<LI>Baxalta spin-off from Baxter International was reported in March 2014 ahead of a July 2015 split.<wbr>
</LI>
</UL> </div></div><a name="oncology10442attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10442_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10442">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-29T15:13:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-29T15:13:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Director of Poland's HTA Agency Disagrees with Transparency Council on Reimbursement of Xofigo</title>
	<pubDate>2015-04-28T16:52:34+02:00</pubDate>
	<wp:post_id>6193</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At its 10th session of 2015 on 30 March, the Transparency Council (TC) of the Polish Agency for Health Technology Assessment and Tariff System (AOTMiT) stated that it considered it reasonable to add Bayer's drug Xofigo (radium-223) to the reimbursement list in the treatment of bone metastases in the course of advanced CRPC.<wbr> The TC stated that it considered the full reimbursement of the drug reasonable within the context of the existing reference group, with the condition that the producer reduces the price of the drug to a level within the AOTMiT's cost-effectiveness threshold.<wbr> The TC did not accept the risk-sharing agreement proposed by the company.<wbr> However, the director of the AOTMiT, Wojciech Matusewicz, did not recommend reimbursement of the drug.<wbr> </div><div style="margin-bottom: 10px;">He expressed concerns about the drug programme proposed by the producer and stated that considering what he deemed as the lack of difference between the health effects gained through treatment with Xofigo compared with Zytiga (abiraterone acetate; Johnson &amp; Johnson, J&amp;J, US), Xofigo was not a financially attractive option at the current proposed cost of treatment.<wbr> Matusewicz stated that the reimbursement of Xofigo was recommended on the condition that monthly treatment costs with the drug would not be higher than those covered by the public payor for Zytiga and provided that Bayer changes the proposed drug programme criteria.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This recommendation is consistent with a new trend of endorsements by the AOTMiT in which the TC considers the reimbursement of a drug reasonable, but the agency's director has taken a much harsher line.<wbr> </div><div style="margin-bottom: 10px;">A similar recommendation was issued for hepatitis C virus drug Olysio (simeprevir; J&amp;J) on the same day as the Xofigo recommendation, and, despite the director's strict recommendation conditions, Olysio was included as one of the new drugs to be added to the reimbursement list from the beginning of May.<wbr> </div><div>Source: IHS GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10439">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-28T16:52:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-28T16:52:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Carcinoid NETs Mobile App Launched In The US & Canada</title>
	<pubDate>2015-04-28T16:06:36+02:00</pubDate>
	<wp:post_id>6194</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: News of its development came late last year and now it is finally 
available on the Web, on App store℠ and on Google Play™ only in the United 
States and Canada and is free to use.<wbr> International versions may become 
available in the future.<wbr> </div><div style="margin-bottom: 10px;">The <STRONG>Carcinoid NETs self-care tool</STRONG>, powered by <STRONG>Health 
Storylines™</STRONG> allows you to track your mood, symptoms, and more, on the 
same timeline as your treatment.<wbr> The Carcinoid NETs app makes sure you have an 
accurate, shareable record of your experience between physician visits, and 
helps you and your care team discover the treatment strategies that are working 
best for you.<wbr> </div><div style="margin-bottom: 10px;">With the <STRONG>Carcinoid NETs app</STRONG>, you can engage in a range of 
Health Tools that help you better manage your health: </div><div style="margin-bottom: 10px;"><UL><LI>Set <STRONG>medication reminders</STRONG> so you don’t forget a to take 
  them </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Track <STRONG>symptoms</STRONG> to monitor how you’re doing over 
time</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Remember important dates and events related to your health with 
  a   health <STRONG>calendar</STRONG></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Note your <STRONG>health concerns</STRONG> so you don’t forget your 
  questions the next time you visit your doctor</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Use a <STRONG>food photo blog</STRONG> to become more mindful of what you 
  eat, and record if certain foods cause heath reactions </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Take a snapshot of all your important <STRONG>health documents</STRONG> 
  and access them easily on the app anytime, anywhere</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Document your health and daily living with a 
<STRONG>journal</STRONG></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Invite the people who care for you to connect as part of your 
  <STRONG>Circle of Support</STRONG>.<wbr> Share your progress with them in real 
  time.<wbr> Let them empower you with their support and encouragement, give you a 
  boost when you need it, and celebrate your milestones.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8037_1_ScreenCapture1.jpg"> </div><div>Source: <A href="http://www.carcinoid.org/content/new-%E2%80%93-carcinoid-nets-mobile-app-%E2%80%93-keeping-track-your-health-just-got-easier">http:/<wbr>/<wbr>www.<wbr>carcinoid.<wbr>org/<wbr>content/<wbr>new-%E2%80%93-carcinoid-nets-mobile-app-%E2%80%93-keeping-track-your-health-just-got-easier</A> </div><!-- Comment details --><a name="endocrinology8037attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8037_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8037">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-28T16:06:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-28T16:06:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prana's PBT2 Recommended for Orphan Drug Designation in EU</title>
	<pubDate>2015-04-28T15:46:56+02:00</pubDate>
	<wp:post_id>6195</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In September last year the US FDA granted PBT2 orphan drug status for the treatment of Huntington disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In February 2014 Prana announced that PBT2 had met its PE of safety and tolerability, and improved measures of cognitive performance – a secondary endpoint in its REACH2HD Phase 2 clinical trial involving 109 people with Huntington disease.<wbr> </div><div>Source:<A href="http://www.sciencedirect.com/science/article/pii/S1474442214702625">http:/<wbr>/<wbr>www.<wbr>sciencedirect.<wbr>com/<wbr>science/<wbr>article/<wbr>pii/<wbr>S1474442214702625</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology8040c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Prana's PBT2 for Huntington Recommended for ODD in EU</span> </div><div style="margin-bottom: 10px;">Prana Biotechnology today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington’s disease.<wbr> </div><div>The approval was based on the recommendation of a positive opinion from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7995">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-28T15:46:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-28T15:46:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Evidence Presented At ASCO GU Does Not Favour Firmagon Claimed CV Benefit</title>
	<pubDate>2015-04-28T13:58:50+02:00</pubDate>
	<wp:post_id>6196</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left" dir="ltr">Comment: Ferring&rsquo;s promotional effort has long been focused on "Firmagon&rsquo;s CV benefit versus GnRH agonists"; at ASCO GU 2015 new data presented may counteract their positioning.<wbr> Their exploratory analysis from CS37 trial showed an updated CV event data namely same number of CV events in degarelix group 3 (3.<wbr>4%) but only 8 (14.<wbr>5%) (instead of 10) in leuprolide group (new HR=0.<wbr>22; 95% CI 0.<wbr>05&ndash;1.<wbr>03, p=0.<wbr>054) &ndash; this is significantly lower than those previously reported by Albertsen et al.<wbr>(2014) and this may change their conclusion.<wbr> Confirmation has been provided by Pr Tombal through the Belgian affiliate.<wbr> This evidence may strengthen Decapeptyl&rsquo;s position versus Firmagon.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Below is the the detail of the poster abstract:</P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Title: Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Background and Objective: Androgen deprivation therapy (ADT) has been associated with increased cardiovascular (CV) risk in men.<wbr> A pooled analysis of phase 3 trials comparing LHRH agonists with degarelix in PCa patients indicated a lower risk of CV events or death in those treated with degarelix.<wbr> We now report the incidence of non-fatal CV events in men with PCa and pre-existing CV disease (CVD) treated with degarelix or leuprolide in the CS37 trial.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Methods: CS37 was a prospective, randomized trial comparing intermittent (n=175) and continuous (n=50) degarelix with continuous leuprolide (n=178) in patients with biochemical relapse of PCa in the United States.<wbr> CV events were retrospectively analyzed up to Month 12 (intermittent arm events censored at Month 7).<wbr> Cox regression models were used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI).<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Results: 143 men (35%) had pre-existing CVD at baseline; 88 treated with degarelix and 55 treated with leuprolide.<wbr> For degarelix and leuprolide treatment arms, median age (range) was 75 (51&ndash;88) and 73 (53&ndash;89) years and median BMI (range) 28.<wbr>0 (17.<wbr>7&ndash;40.<wbr>7) and 30.<wbr>1 (23.<wbr>5&ndash;48.<wbr>3) kg/<wbr>m2, respectively.<wbr> A slightly higher proportion of men treated with leuprolide than degarelix had a Gleason score of 7&ndash;10 (35 [64%] vs 46 [52%]) and slightly more men treated with degarelix vs leuprolide had hypertension (27 [31%] vs 13 [24%]), diabetes (70 [80%] vs 39 [71%]) and used statin medication (67 [76%] vs 36 [65%]) at baseline.<wbr> The proportion of men who smoked or had hypercholesterolemia at baseline was similar between treatment arms.<wbr> During the observation period, a subsequent CV event occurred in 3 (3.<wbr>4%) men treated with degarelix and 8 (14.<wbr>5%) treated with leuprolide (new HR=0.<wbr>22; 95% CI 0.<wbr>05&ndash;1.<wbr>03, p=0.<wbr>054).<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Conclusions: Retrospective analysis of men with pre&minus;existing CVD in CS37 identified a lower risk for subsequent CV events in men treated with degarelix vs leuprolide (but not significant anymore).<wbr> CV events were apparent within 14 months of treatment initiation.<wbr> Prospective trials that specifically evaluate CV endpoints over longer periods of time should be conducted to verify these retrospective observations.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10437_1_ASCO%20GU%202015%20%2d%20Firmagon%20analysis.JPG"></P> </div><div><P align="left" dir="ltr">Source: Belgium UroOnco BU, ASCO GU 2015 J Clin Oncol 33, 2015 (suppl 7; abstr 151)</P> </div><!-- Comment details --><a name="oncology10437attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10437_1_ASCO%20GU%202015%20%2d%20Firmagon%20analysis.JPG">ASCO GU 2015 - Firmagon analysis.JPG</a>&nbsp;&nbsp;(3,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10437">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-28T13:58:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-28T13:58:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Revive Signs Research Collaboration with Rettsyndrome.org</title>
	<pubDate>2015-04-28T11:20:30+02:00</pubDate>
	<wp:post_id>6197</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Revive Signs Research Collaboration with Rettsyndrome.<wbr>org</span>&nbsp;<br><span style="font-size: 12px;">Comment: Revive will supply the drug to conduct the study under the Rettsyndrome.<wbr>org Scout Program.<wbr> The objective of the study is to run a behavioral battery of tests to screen and assess the potential for REV-003 (Tianeptine) for Rett syndrome in a mouse model.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=7918">...</a><br></div><div style="margin-bottom: 10px;">Revive has announced positive study results of REV-003 (Tianeptine) from its research collaboration with Rettsyndrome.<wbr>org.<wbr> The study results assessed body weight, grip strength, gait analysis, and neurologic and behavioral parameters.<wbr> The drug was well-tolerated and had no effects on body weight, improved motor coordination in the rotarod test, reduced clasping to almost normal levels, normalized prepulse inhibition of startle at the higher dose, and significantly improved gait features, in particular the positioning of the paws.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Full results</STRONG> of the study, including replication and expansion to other functional domains, will soon be published.<wbr> </div><div>As part of the research collaboration, Revive supplied the drug to conduct the study, and all raw data, samples and specimens arising from the performance of this study remain properties of Revive.<wbr> The study was performed by PsychoGenics Inc.<wbr>, funded and managed by Rettsyndrome.<wbr>org.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8036">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7918">View thread  Endocrinology7918: Revive Signs Research Collaboration with Rettsyndrome.<wbr>org</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-28T11:20:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-28T11:20:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alliance Between Industry and Academic Teams Formed to Develop New Therapies for IBD</title>
	<pubDate>2015-04-28T11:07:55+02:00</pubDate>
	<wp:post_id>6198</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Second Genome, Inc.<wbr>, a leader in the development of novel medicines through innovative microbiome science, has entered into an alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC), Ireland, to explore the role of the microbiome in IBD by analyzing data from patients to identify new opportunities for therapeutic intervention.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to identify bacterial species and mechanisms that are driving IBD biology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Second Genome has assembled a one-of-a-kind drug discovery platform that integrates microbiome and host biology for the identification of novel targets and drugs.<wbr> </div><div style="margin-bottom: 10px;">APC Microbiome Institute has deep clinical and bacterial culturing expertise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Second Genome</STRONG> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;">Lead candidate SGM-1019 entered Ph1 at the beginning of 2015.<wbr> The drug is an orally delivered small molecule initially being developed by Second Genome for the treatment of Crohn’s disease.<wbr> </div><div style="margin-bottom: 10px;">Former Pfizer executive to lead R&amp;D.<wbr> </div><div style="margin-bottom: 10px;"><U>Parterships</U> </div><div style="margin-bottom: 10px;">Mayo Clinic (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2059" class="defaultlink">GastroEnterology2059: Second Genome Ink Agreement with Mayo Clinic to Develop Microbiome Therapeutics</a>); Pfizer on microbiome research initiative in obesity; Janssen on microbiome drug discovery in UC </div><div style="margin-bottom: 10px;"><STRONG>APC Microbiome Institut</STRONG> </div><div style="margin-bottom: 10px;">Irish research institute for diet, medicine and the microbiome, funded by Science Foundation Ireland and industry partners.<wbr> The APC, a partnership between University College Cork, the Irish Agriculture and Food Development Authority (Teagasc), and the Cork Institute of Technology, carries out research on the gastrointestinal bacterial community (the microbiome).<wbr> </div><div style="margin-bottom: 10px;"><U>Recent Industry Partnership</U> </div><div>March 16 2015 - J&amp;J to explore the role of viruses in shaping the human microbiome and their potential use as novel treatments and/<wbr>or biomarkers of inflammatory bowel disease.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2325">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-28T11:07:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-28T11:07:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on the Check-Cap Imaging System</title>
	<pubDate>2015-04-27T15:43:56+02:00</pubDate>
	<wp:post_id>6199</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Check-Cap has received a Notice of Allowance from the USPTO for patent application U.<wbr>S.<wbr> 13/<wbr>825,018.<wbr> If granted patent is expected to be valid through 2031.<wbr> In addition, management outlined it will be filing for a CE mark this year, and initiating a clinical trial for FDA approval during 2016.<wbr> The ingestible imaging capsule is rooted in technology that does not require bowel preparation or invasive procedures, like other ingestible capsules or the traditional colonoscopy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">"Estimation of Distances and Size of Lesions in the Colon with an Imaging Capsule.<wbr>" </div><div style="margin-bottom: 10px;"><UL><LI>The patent broadly covers Check-Cap's investigational preparation-free endoscopy capsule with a colon imaging system for detecting colorectal cancer and clinically-significant pre-cancerous polyps, and outlines a method for measuring distances inside a patient's colon and optionally using the measurements to construct an image of the inside of the colon.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In late 2015, Check-Cap plans to file for a CE mark for the marketing and sale of the Company's endoscopy capsule in the European Union, and expects to perform post-marketing studies in Europe following CE marking for the purpose of collecting additional clinical data to support market adoption.<wbr> </div><div style="margin-bottom: 10px;">Check-Cap anticipates initiating a clinical trial for FDA approval during 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2323_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2323_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">It consists of an ingestible capsule that transmits colon section measurements through a radio frequency (RF) link to a data recorder.<wbr> </div><div style="margin-bottom: 10px;">The single-use, disposable capsule is approximately 34 millimeters long and 11.<wbr>5 millimeters wide, making it similar in size to other capsule endoscopy products.<wbr> It advances through the body by natural motility, painlessly capturing and continuously transmitting data reflecting the colon's internal surface with the help of a contrast agent before being excreted naturally within two to three days.<wbr> </div><div style="margin-bottom: 10px;">Patients are able to continue their normal daily routines throughout the process including normal food intake.<wbr> </div><div style="margin-bottom: 10px;">Upon test completion, gastroenterologists or radiologists can analyze the data from any computer in less than 10 minutes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2009 </div><div style="margin-bottom: 10px;">Check-Cap is a clinical-stage medical diagnostics company, based in Israel.<wbr> </div><div style="margin-bottom: 10px;">Market Cap: approx $43.<wbr>41M </div><div style="margin-bottom: 10px;">Check-cap is the only product in the company pipeline/<wbr>portfolio.<wbr> </div><div>Recent results of a survey conducted in 502 patients suggest that an imaging capsule like Check-Cap could contribute to screening adherence among patients who decline colonoscopy (<A href="http://www.check-cap.com/pdf/Potential_Screening_Benefit_of_a_Colorectal-98841.pdf">http:/<wbr>/<wbr>www.<wbr>check-cap.<wbr>com/<wbr>pdf/<wbr>Potential_Screening_Benefit_of_a_Colorectal-98841.<wbr>pdf</A> - Potential Screening Benefit of a Colorectal Imaging Capsule That Does Not Require Bowel Preparation).<wbr> </div><!-- Comment details --><a name="gastroenterology2323attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2323_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(92,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2323_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(20 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2323">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-27T15:43:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-27T15:43:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Esmya(R) Granted EMA for Uterine Fibroids</title>
	<pubDate>2015-04-27T11:58:48+02:00</pubDate>
	<wp:post_id>6200</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Esmya(R) Granted EMA for Uterine Fibroids</span>&nbsp;<br><span style="font-size: 12px;">Comment: The EC has granted marketing authorization to Richter/<wbr>PregLem's Esmya(R) 5mg tablet for pre-operative treatment of moderate to severe symptoms of uterine fibroids.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=8125">...</a><br></div><div>The EMA has positively assessed Richter's application to extend the indication of its Esmya tablets to the long-term treatment of symptoms of uterine fibroids.<wbr> The Agency's positive opinion would be forwarded to the European Commission, which is expected to amend the marketing authorisation for Esmya for all countries of the European Union, within two months.<wbr><BR><BR>Esmya's initial EU marketing licence was for the pre-operative treatment of moderate-to-severe symptoms of uterine fibroids in adult women.<wbr><BR><BR>"The extension of indication to include the repeated intermittent treatment will give, should it be approved, the opportunity to many women suffering from this condition to be relieved from the symptoms of fibroids," Richter said in a statement on the Budapest bourse's website.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10436">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8125">View thread  Oncology8125: Esmya(R) Granted EMA for Uterine Fibroids</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-27T11:58:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-27T11:58:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BioGaia Website Highlights Positive Results in Chinese Study with Drops of Lactobacillus reuteri Protectis</title>
	<pubDate>2015-04-27T11:34:34+02:00</pubDate>
	<wp:post_id>6201</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The results from a Chinese study of infants with colics show that babies given <EM>Lactobacillus reuteri </EM>Protectis cry significantly less compared to babies given placebo.<wbr> Management has reported this study strengthens BioGai position in the paediatric field, and outlined that the company now has strong data in this field from a study conducted in China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://news.cision.com/biogaia/r/positive-results-in-first-chinese-study-with-biogaia-s-drops-in-infants-with-colic,c9763363">http:/<wbr>/<wbr>news.<wbr>cision.<wbr>com/<wbr>biogaia/<wbr>r/<wbr>positive-results-in-first-chinese-study-with-biogaia-s-drops-in-infants-with-colic,c9763363</A> </div><div style="margin-bottom: 10px;">Title: Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial </div><div style="margin-bottom: 10px;"><UL><LI><U>Principal investigators</U> Guo-Lin Mi, Shandong University School of Medicine and Shandong Mental Health Center, both Jinan, Shandong, China Lei Zhao, Neonatal Intensive care Unit, Children’s Hospital of Zhengzhou, Zhengzhou, Henan, China </LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Study objective</U>: to evaluate the effectiveness of L.<wbr> reuteri DSM 17938 (L.<wbr> reuteri Protectis) for the treatment of infantile colic in predominately and exclusively breastfed infants, as compared to placebo.<wbr> </div><div style="margin-bottom: 10px;"><U>Study design</U>: placebo-controlled, randomized trial in 42 predominately and exclusively breastfed infants diagnosed with infantile colic and less than four months of age.<wbr> </div><div style="margin-bottom: 10px;"><U>Regimen</U>: the infants were assigned to receive either 5 drops (1x108 cfu) of Lactobacillus reuteri Protectis (n=21) or placebo (n=21) daily for 21 days.<wbr> </div><div style="margin-bottom: 10px;"><U>Duration</U>: the infants were followed for four weeks.<wbr> </div><div style="margin-bottom: 10px;"><U>Outcome parameters</U> </div><div style="margin-bottom: 10px;">Primary outcome was treatment success, that is the reduction in daily average crying time of 50 per cent or more from study start to the end of the study.<wbr> </div><div style="margin-bottom: 10px;">Secondary outcomes were mean reduction of daily crying time, parent satisfaction and reduction in maternal depression.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>100 per cent treatment success </STRONG> </div><div style="margin-bottom: 10px;">Treatment succes was observed in all infants supplemented by <EM>Lactobacillus reuteri </EM>Protectis while it was seen in barely 16 per cent of the placebo group.<wbr> In addition, the study showed 100 per cent parent satisfaction in the <EM>Lactobacillus reuteri </EM>Protectis group, while barely 16 percent among parents of children in the placebo group reported treatment satisfacion.<wbr> 42 infants were included in the study.<wbr> </div><div>Source: BioGaia </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2322">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-27T11:34:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-27T11:34:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Radium-223 dichloride (radium-223) Under Review in Japan</title>
	<pubDate>2015-04-27T11:07:10+02:00</pubDate>
	<wp:post_id>6202</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer has submitted an application to the Ministry of Health, Labour and Welfare.<wbr> The regulatory submissionhas been based on data from the Ph3 ALSYMPCA as well as data from additional trials to assess the safety and efficacy of the drug in Japanese patients.<wbr> Long-term safety data on radium Ra 223 dichloride will be presented @ ASCO GU 2015 (please see below).<wbr> </div><div style="margin-bottom: 10px;"><B>Radium Ra 223 Dichloride (radium-223)</B> </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: disc" type="disc"><LI><I>Effect of radium-223 dichloride (Ra-223) on pain from US expanded access program (EAP)</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 160, Board G22, General Poster Session A: Prostate Cancer </LI>
<LI>Thursday, February 26, 11:30 AM – 1:00 PM (EST) </LI>
</UL></LI>
<LI><I>External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 182, Board H18, General Poster Session A: Prostate Cancer </LI>
<LI>Thursday, February 26, 11:30 AM – 1:00 PM (EST) </LI>
</UL></LI>
<LI><I>3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) From ALSYMPCA</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 195, Board J5, General Poster Session A: Prostate Cancer </LI>
<LI>Thursday, February 26, 11:30 AM – 1:00 PM (EST) </LI>
</UL></LI>
<LI><I>Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/<wbr>2a clinical trial</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 202, Board J12, General Poster Session A: Prostate Cancer </LI>
<LI>Thursday, February 26, 11:30 AM – 1:00 PM (EST) </LI>
</UL></LI>
<LI><I>Radium-223 dichloride (Ra-223) in U.<wbr>S.<wbr> expanded access program (EAP)</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 247, Board C16, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma </LI>
<LI>Friday, February 27, 12:15 – 1:45 PM (EST) </LI>
</UL></LI>
<LI><I>Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 253, Board C22, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma </LI>
<LI>Friday, February 27, 12:15 – 1:45 PM (EST) </LI>
</UL></LI>
<LI><I>Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup</I> 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>Abstract 254, Board C23, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma </LI>
<LI>Friday, February 27, 12:15 – 1:45 PM (EST) </LI>
</UL></LI>
</UL> </div><div>Source: Bayer </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10433">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-27T11:07:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-27T11:07:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer to Evaluate Visanne in Real Life in Asian Women with Endometriosis</title>
	<pubDate>2015-04-24T16:36:24+02:00</pubDate>
	<wp:post_id>6203</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The ENVISIOeN trial will be conducted in routine clinical practice settings.<wbr> It is planned to recruit approx 870 patients with endometriosis for whom a decision has been made by the physician to treat with dienogest according to local health authority approved label.<wbr> PE will measure the mean change from baseline to 6 months of treatment in pain-related Quality of Life measured by EHP-30.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reference NCT02425462 </div><div style="margin-bottom: 10px;">Timelines Trial planned to start this month and complete Sept 2018 /<wbr> Dec 2018 </div><div style="margin-bottom: 10px;"><P>Recruitment approx 870
<!--generated--></P> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Asian Female patients at least 18 years of age</LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Clinical or surgical diagnosis of endometriosis (depending on local approved indication) : Clinical diagnosis by suggestive symptoms and positive finding in imaging study (Chocolate cyst)</LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with Endometriosis associated pelvic pain - Decision taken by the physician to newly prescribe Visanne®</LI> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Location 6 sites (Indonesia; Rep of Korea; Malaysia; Philippines; Singapore; Thailand)</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10432">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-24T16:36:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-24T16:36:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</title>
	<pubDate>2015-04-24T16:12:10+02:00</pubDate>
	<wp:post_id>6204</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</span>&nbsp;<br><span style="font-size: 12px;">Comment: <EM>Clinicaltrials.<wbr>gov</EM> is listing two US registration trials of DWP-450 to treat glabellar lines.<wbr> Both studies (EV001 and EV002) will enroll approx.<wbr> 324 subjects each, be randomly assigned 3:1 to receive DWP-450 or placebo, and have same timelines and PE (reduction in GL as assessed by investigator and subject).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7880">...</a><br></div><div style="margin-bottom: 10px;"><P align="left">ALPHAEON has completed enrollment of the two pivotal studies which marks a significant milestone for the Ph3 development program.<wbr></P> </div><div><P align="left">Recruitment for the two U.<wbr>S.<wbr>-based studies began on January 2015 and was completed in March.<wbr></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7994">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7880">View thread  Neurology7880: Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-24T16:12:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-24T16:12:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from Novartis Q1:15 Performance</title>
	<pubDate>2015-04-24T13:17:51+02:00</pubDate>
	<wp:post_id>6205</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net sales increased by 3% (in cc) to $11,935m.<wbr> Sandoz delivered strong results (+9%) driven by biosimilars and emerging growth markets.<wbr> Management highlighted the company is strengthening its position in immuno-oncology (IO), and will have 3 compounds in the clinic this year.<wbr> Planned filings in Cushing's are expected in 2016 for Signifor LAR, and 2017 for LCI699.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL class="hugin" type="circle"><LI class="hugin">Three approvals in Oncology: <I class="hugin">Jakavi</I> in polycythemia vera (EU), <I class="hugin">Farydak</I> in multiple myeloma (US) and <I class="hugin">Jadenu</I> for chronic iron overload (US)</LI>
<LI class="hugin">LCZ696 granted FDA priority review and CHMP accelerated assessment in heart failure</LI>
<LI class="hugin">Positive trials on <I class="hugin">Cosentyx</I> in psoriasis showing superiority to Stelara®, sustained two-year efficacy</LI>
<LI class="hugin">Sandoz received FDA approval for first biosimilar <EM class="hugin">Zarxio</EM> and in April for first substitutable generic version of Copaxone® 20mg one-time-daily injection, <I class="hugin">Glatopa</I></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="endocrinology8032attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(41,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8032_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(39,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8032">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-24T13:17:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-24T13:17:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GTx Licenses SARD Technology from U. of Tennessee Research Foundation (UTRF)</title>
	<pubDate>2015-04-24T11:47:43+02:00</pubDate>
	<wp:post_id>6206</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: UTRF's proprietary selective androgen receptor degrader (SARD) technology potentially can degrade and inhibit all forms of androgen receptor (AR), including those resistant to current therapies, in patients with progressive CRPC.<wbr> The Universiy has a large array of technologies listed across multiple categories that can be searched and licensed such as <A href="http://utrf.technologypublisher.com/technology/17595">nanoparticle formulation of anticancer agents </A>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to GTx management "The lack of activity of current therapies in approximately one-third of patients makes the SARD technology we have licensed from UTRF very attractive due to the potential to develop compounds that not only degrade AR but also the splice variant mutations, thereby providing a potential novel therapy for the thousands of men who suffer from castration-resistant prostate cancer".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GTx will host a conference call and webcast on Friday, May 8, at 9:00 a.<wbr>m.<wbr> Eastern Time, to provide a corporate update on the Company's preclinical and clinical development initiatives, including a discussion of its near term plans for the licensed SARD technology, and its first quarter 2015 financial results.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><A href="http://utrf.technologypublisher.com/searchresults.aspx?q=Human+Health&amp;type=c">http:/<wbr>/<wbr>utrf.<wbr>technologypublisher.<wbr>com/<wbr>searchresults.<wbr>aspx?q=Human+Health&amp;type=c</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10429">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-24T11:47:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-24T11:47:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from AstraZeneca Q1:15 Results</title>
	<pubDate>2015-04-24T10:51:26+02:00</pubDate>
	<wp:post_id>6207</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Total revenues increased by 1% to $6,057m.<wbr> Product sales declinded 3%, largely reflecting entry of generic Nexium in the US, where sales of the drug fell by -53%.<wbr> The beat was driven by “externalization revenues” (contribution from divestments reached $309m vs $44m in Q1:14).<wbr> Strong 'Emerging markets' results driven by a stellar China (+28%).<wbr> On a pipeline side, management highlighted 13 NMEs in Ph3/<wbr>Registration, and indicated that the Onco Franchise now has 72 trials ongoing, including 31 in immuno-oncology.<wbr> CEO said no comment on Pfizer.<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CEO says Celgene deal will: </div><div style="margin-bottom: 10px;"><UL><LI>
bring PD-L1 to patients much faster</LI>
<LI>
unlock value that AZ could not unlock by itself </LI>
<LI>
have to price immuno-oncology combinations at appropriate level to maximise access</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology10427attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(81 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10427_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(80,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10427">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-24T10:51:26+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-24T10:51:26+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie Reports Strong Humira Sales</title>
	<pubDate>2015-04-23T18:09:16+02:00</pubDate>
	<wp:post_id>6208</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sales of Humira jumped 18% to $3.<wbr>11 billion in the first quarter, representing about two-thirds of total revenue.<wbr> AbbVie agreed last month to buy Pharmacyclics <PCYC.O>for about $21 billion to reduce its dependence on Humira, and expand its cancer drug pipeline </PCYC.O> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10426_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10426_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10426_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology10426attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10426_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10426_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(75,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10426_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(105,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10426">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-23T18:09:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-23T18:09:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BioGaia's Lactobacillus Reuteri ATCC PTA 6475 to Enter POC for Osteopenia</title>
	<pubDate>2015-04-23T17:53:46+02:00</pubDate>
	<wp:post_id>6209</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The double-blind, placebo-controlled, randomized study is designed to investigate if dietary supplementation with L.<wbr> reuteri twice daily for 12 months has any effect on bone density, body composition, inflammation, or metabolic and endocrine markers in elderly women with osteopenia.<wbr> PE will measure the change in total tibia volumetric bone mineral density compared to placebo group after 1 year of dietary supplementation with L.<wbr> reuteri.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Reference NCT02422082 </div><div style="margin-bottom: 10px;">- Recruitment n=90 women (75 to 80 years) </div><div style="margin-bottom: 10px;"><UL><LI>bone mineral density T-score less than -1 but more than -2.<wbr>5 in the total hip or lumbar spine (L1-L4) by dual energy x-ray absorptiometry.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">- Location: Sahlgrenska University Hospital, Sweden </div><div style="margin-bottom: 10px;">- Timelines </div><div>Trial planned to start this month, and complete April 2016 /<wbr> June 2016 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2321">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-23T17:53:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-23T17:53:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alphaeon Launches New Cloud Based Aesthetic Marketing Tool</title>
	<pubDate>2015-04-23T12:32:54+02:00</pubDate>
	<wp:post_id>6210</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Alphaeon has announced the launch of </SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7991_2_ScreenCapture2.jpg"></P> </div><div style="margin-bottom: 10px;"><P align="left">Alphaeon's focus on technology as part of its marketing was also very evident at IMCAS this year where it was demonstrating its other on-line portal ShoutMD its unique crowd intelligence platform that allows physician specialists to share insights, start discussions and collaborate with peers to improve the patient experience and outcomes.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Interestingly the Strathspey Crown Booth (Alphaeon's holding company) featured a list of all the founding/<wbr>investors (clinicians) in the company of which there are a significant number (see below).<wbr></P> </div><div><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7991_3_ScreenCapture3.jpg"></P> </div><!-- Comment details --><a name="neurology7991attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7991_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(112 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7991_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(115,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7991_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(142 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7991">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-23T12:32:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-23T12:32:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan PhIII Adult Lower Limb Spasticity Results</title>
	<pubDate>2015-04-23T11:53:19+02:00</pubDate>
	<wp:post_id>6211</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Presented yesterday in an oral session at the AAN meeting were the phIII results of Allergan's post stroke ALL trial.<wbr> The results demonstrated that a single onabotulinumtoxinA (300-400U) as early as week 3 lowered or reduced post-stroke spasticity in the lower limbs.<wbr> The improvement in muscle tone was clinically meaningful and complimented by significant improvements in global functioning as measured by CGI and GAS, at some timepoints.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><STRONG>Study Design</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>
<SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN></SPAN>

</LI>
<LI>
<SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN></SPAN>

</LI>
<LI>
<SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN></SPAN>

</LI>
<LI>
<SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN></SPAN>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_1_ScreenCapture1.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><STRONG>Post-Stroke ALL Results</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN> <SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_2_ScreenCapture2.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_3_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_4_ScreenCapture5.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">The results of the study were also presented in poster form a copy of which is attached to download.<wbr> Some other key data is shown below</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_5_ScreenCapture6.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_6_ScreenCapture7.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_9_ScreenCapture9.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_7_ScreenCapture8.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"><STRONG>Xeomin (incobotulinumtoxinA) &ndash; Merz</STRONG></SPAN> <SPAN lang="EN-US" style="mso-ansi-language: EN-US;">Merz also represented top-line results from its phIII post-stroke upper limb spasticity study 1st highlighted at the AAPMR meeting last year.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;">317 patients with stroke over 3 months ago, flexed elbow, wrist, and clenched fist &gt;/<wbr>=2 on Ashworth scale</SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;">Total dose of 400 U &ndash; elbow 200, wrist 150, fist 100, with 100 U to use elsewhere &ndash; vs.<wbr> placebo</SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;">Trial had a high number of Asian patients as there were a few sites in India</SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;">Secondary outcomes are currently being analyzed</SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;">There is an open-label extension trial ongoing, every 12 weeks for 36 weeks</SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;">There was a trial amendment after 58 patients in accordance with guidance by the FDA</SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;"><STRONG>Results:</STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US;">IncoA reduced AS scores significantly at week 4 and responder rates were superior at week 4, 6, and 8</SPAN></SPAN>
</LI>
<LI><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"> <SPAN lang="EN-US" style="mso-ansi-language: EN-US;">Investigators&rsquo; Global Impression of Change was also significantly superior and 42% were very much better vs.<wbr> 23% in the placebo group and Disability Assessment Scale was also significantly better</SPAN></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: arial,helvetica,sans-serif; font-size: small; mso-ansi-language: EN-US;"><STRONG>Regulatory:</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-fareast-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><SPAN lang="EN-US" style="mso-ansi-language: EN-US;">A knowledgeable industry expert said that Merz submitted in November and expects approval Q4 2015; <EM>&ldquo;right after Dysport or maybe at the same time&rdquo;</EM></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN lang="EN-US" style="mso-fareast-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><SPAN lang="EN-US" style="mso-ansi-language: EN-US;">According to a company employee/<wbr>physician, 400 U is the dose that has been submitted, not higher</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Thanks to our vendor covering this meeting slides of the Merz data are available if required.<wbr></SPAN> </div><div><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Source: Day 4 AAN Meeting Washington DC</SPAN> </div><!-- Comment details --><a name="neurology7987attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(136,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(127,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(113,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(110,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(40,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(34,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_8_Allergan%20Poster%20PhIII%20Post%20Stroke%20ALL%20Data.pdf">Allergan Poster PhIII Post Stroke ALL Data.pdf</a>&nbsp;&nbsp;(581,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7987_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(62,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7987">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-23T11:53:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-23T11:53:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi Management Expects Strong YoY Growth in Line with Previous Guidance</title>
	<pubDate>2015-04-23T11:21:43+02:00</pubDate>
	<wp:post_id>6212</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: CEO noted that company total sales for Q1:15 (MSEK 68.<wbr>9) are more than double the figure for Q1:14.<wbr> This growth being very much attribuable to stock accumulation by Pharmavite and NBTY prior to future launches later this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the first quarter, Probi’s net sales totalled MSEK 68.<wbr>9 (26.<wbr>4).<wbr> The overall increase was MSEK 42.<wbr>5, corresponding to 161%.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2320_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2320_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2320_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology2320attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2320_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2320_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2320_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(39,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2320">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-23T11:21:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-23T11:21:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages fom Roche First Quarter</title>
	<pubDate>2015-04-22T19:30:37+02:00</pubDate>
	<wp:post_id>6213</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pharmaceuticals Division sales increased by 4%: strong growth in oncology (HER2-positive breast cancer medicines, Avastin, MabThera/<wbr>Rituxan) and immunology (Actemra/<wbr>RoActemra, Xolair).<wbr> Management reported extensive Ph3 program to start in 2015 in cancer immunotherapy.<wbr> For this year, Roche repeated it expects low- to mid-single-digit sales growth and for core earnings per share to grow ahead of sales, if exchange rates remained constant.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="oncology10423attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(24,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(121,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10423_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(107,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10423">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-22T19:30:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-22T19:30:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Generic Megamerger Rumours Confirmed As Teva Bids $40bn for Mylan</title>
	<pubDate>2015-04-22T19:07:00+02:00</pubDate>
	<wp:post_id>6214</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:-  <ORG value=";NYSE:TE">Teva today 
announced a proposal to acquire all of the outstanding shares of </ORG><ORG value="NASDAQ-NMS:MYL">Mylan in a transaction valued at 
<MONEY>$82.<wbr>00</MONEY> per Mylan share, with the consideration based 
on approximately 50 percent cash and 50 percent stock.<wbr> The bid is delivered 
in a week when  the FDA approved the first substitutable generic form 
of Copaxone.<wbr> Copaxone generated 21% of the company's top-line in 2014, and  
a significantly higher percentage contribution to profits and cash flow from 
operations</ORG> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Teva is suggesting that its proposal also provides Mylan stockholders 
with a more attractive alternative to Mylan’s proposed acquisition of <ORG value="NYSE:PRGO">Perrigo Company plc</ORG> announced on 
<CHRON>April 8, 2015</CHRON>, as well as to Mylan on a standalone basis.<wbr> </div><div style="margin-bottom: 10px;">Teva’s proposal would provide Mylan stockholders with consideration 
representing a 37.<wbr>7% premium to the stock price of Mylan on <CHRON>April 7, 
2015</CHRON>, which is the last day of trading prior to Mylan’s press release 
regarding its unsolicited proposal for <ORG value="NYSE:PRGO">Perrigo.<wbr></ORG> </div><div style="margin-bottom: 10px;"><STRONG>What Are The Implications Of The Deal</STRONG> </div><div style="margin-bottom: 10px;">The proposed combination of Teva and Mylan would create a leading company in 
the pharmaceutical industry, well positioned to transform the global generics 
space.<wbr> </div><div style="margin-bottom: 10px;">It is suggested that the combined company would leverage its significantly 
more efficient and advanced infrastructure, with enhanced scale, production 
network, end-to-end product portfolio, commercialization capabilities and 
geographic reach.<wbr> </div><div style="margin-bottom: 10px;">Additionally, the combined company would look to focus on complex 
technologies and more durable and sustainable products, in combination with 
robust capabilities in specialty drug development and commercialization.<wbr> </div><div style="margin-bottom: 10px;">The combined company would also have an enhanced financial profile, creating 
the opportunity for rapid deleveraging and the funding of future growth – in 
generics, specialty and the intersection of the two.<wbr> </div><div style="margin-bottom: 10px;">As one company, it expects to have the infrastructure and 
capabilities to faster pursue a differentiated business model, fully integrating 
specialty and generics drugs with products, devices, services and technologies 
to meet the evolving needs of patients and customers.<wbr> This has echoes of 
Actavis's rational for acquiring Allergan.<wbr> </div><div style="margin-bottom: 10px;">More precisely it has spelt out the rational as shown below:- </div><div style="margin-bottom: 10px;"><I><B>Teva and Mylan Together: Compelling Strategic 
Rationale</B></I> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"><B>Creates an Industry-Leading Company 
  Well-Positioned to Transform the Generics Space: </B>The transaction would 
  create a company with a significantly expanded and more efficient global 
  footprint, including leadership positions and strengthened operations, sales 
  and R&amp;D platforms in attractive markets around the world.<wbr> The combined 
  company would benefit from a robust, industry-leading sales infrastructure and 
  deep customer and provider relationships across the expanded network.<wbr> The 
  result is an even more efficient, flexible and competitive global platform 
  with industry-leading go-to-market capabilities.<wbr><BR><BR>The Teva and Mylan 
  product offerings are highly complementary, and together, would create the 
  broadest portfolio in the industry, with a combined pipeline of over 400 
  pending ANDAs and over 80 first-to-files in the U.<wbr>S.<wbr><BR><BR>Furthermore, the 
  combined company will possess the capabilities and technologies to focus on 
  more complex, hard-to-produce durable products, delivering better value and 
  accessibility, while improving adherence and compliance.<wbr> Teva's capabilities 
  in this field will significantly expand with the addition of Mylan’s 
  ophthalmic products, soft gel caps, topical and inhalant technologies, “Wave 
  2” biosimilars, injectables and alternative dosage forms, and Antiretroviral 
  (ARV) products.<wbr><BR><BR>The combined company would also benefit from the most 
  advanced R&amp;D capabilities in the generics industry and the world’s leading 
  integrated API division.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"><B>Creates a Unique and Differentiated Business 
  Model, Leveraging Significant Assets and Capabilities in Generics and 
  Specialty and the Intersection of the Two:</B> Teva is committed to investing 
  in and growing the combined company’s <MONEY>$10 billion</MONEY> specialty 
  pharmaceuticals business, which it expects will grow stronger, based on 
  combining the separate companies’ standalone offerings.<wbr> The combined company 
  would benefit from leading positions in multiple sclerosis, respiratory, pain, 
  migraine, <STRONG>movement disorders</STRONG> and allergy therapeutics, 
  combined with an enhanced global infrastructure to pursue current and future 
  commercialization.<wbr><BR><BR>Furthermore, the combined company's significantly 
  enhanced financial position and resources would enable it to further invest in 
  its specialty R&amp;D programs and aggressively pursue business development 
  opportunities generating short- and longer-term growth.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><I><B>Significant Financial Benefits of a Combined Teva 
and Mylan</B></I> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"><B>Strong Financial Profile to Drive Future 
  Growth:</B> The combined company would have an enhanced financial profile, 
  creating the opportunity for the funding of future growth.<wbr> The combined Teva 
  and Mylan would have pro forma 2014 revenues of approximately <MONEY>$30 
  billion</MONEY> and pro forma 2014 EBITDA of approximately <MONEY>$9 
  billion</MONEY>.<wbr><BR><BR>The combined company would have a strong long-term 
  growth profile that includes mid-single digit top-line growth, as well as 
  significant non-GAAP EPS growth.<wbr> In 2016, the combined company is expected to 
  have cash flow from operations, excluding one-time restructuring costs, of 
  greater than <MONEY>$6 billion</MONEY>, revenues of greater than <MONEY>$30 
  billion</MONEY> and EBITDA of greater than <MONEY>$10 billion</MONEY>.<wbr> In 
  2018, the combined company is expected to have cash flow from operations of 
  greater than <MONEY>$8.<wbr>5 billion</MONEY>, revenues of approximately <MONEY>$33 
  billion</MONEY> and EBITDA of approximately <MONEY>$13 billion</MONEY>.<wbr> 
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="bwlistitemmargb"><I><B>Timing and 
Approvals</B></I> </P> </div><div style="margin-bottom: 10px;">Teva has carefully studied the regulatory aspects of a combination of Teva 
and Mylan, in conjunction with its advisors.<wbr> Teva is confident that it would be 
able to structure a transaction that would not contain material impediments to 
closing and that it can determine and promptly implement divestitures, as 
necessary, to gain regulatory clearances.<wbr> </div><div style="margin-bottom: 10px;">Teva expects that the proposed transaction can be completed by year-end 2015.<wbr> 
Teva notes that there can be no assurance that a transaction between Teva and 
Mylan will be consummated.<wbr> </div><div style="margin-bottom: 10px;"><I><B>Letter to Mylan</B></I> </div><div>A letter was sent to the Executive Chairman of the Mylan Board of 
Directors on <CHRON>April 21, 2015</CHRON> reiterating many of the points 
mentioned above.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150431&edate=20150401&rec=11156">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-22T19:07:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-22T19:07:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Zytiga Promotional Campaign: J&J Is Holding Workshops Throughout UK</title>
	<pubDate>2015-04-22T17:35:59+02:00</pubDate>
	<wp:post_id>6215</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jassen is sponsoring eight <SPAN style="font: small/16.54px arial, sans-serif; text-align: left; color: #545454; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; float: none; display: inline !important; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">multidisciplinary </SPAN>teaching style workshops throughout UK, advertised by Elsevier Healthcare, to discuss mCRPC management.<wbr> J&amp;J KOLs include Professor Charles Ryan, Professor Eleni Efstathiou, Dr Gordon Brown will be discussing the benefits of earlier treatment initiation, treatment goals, and patients identification in the post-ADT setting, and highlights from three major uro-oncology conferences; ASCO, EAU, and ASCO GU.<wbr> </div><div style="margin-bottom: 10px;">The workshops will be held sequentially in 8 locations including Glasgow, Merseyside, Manchester, Birmingham, Cardiff, Exeter, Oxford, and London.<wbr> The Regional chair will be discussing regional funding , pathways, and treatment environment in mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0"><TBODY><TR><TD>Region</TD>
<TD>Region Chair</TD>
</TR>
<TR><TD>Glasgow</TD>
<TD>Balaji Venugopal</TD>
</TR>
<TR><TD>Merseyside</TD>
<TD>Zafar Malik</TD>
</TR>
<TR><TD>Manchester</TD>
<TD>James Wylie</TD>
</TR>
<TR><TD>Birmingham</TD>
<TD>Nick James</TD>
</TR>
<TR><TD>Cardiff</TD>
<TD>John Staffurth</TD>
</TR>
<TR><TD>Exeter</TD>
<TD>Sarah Pascoe</TD>
</TR>
<TR><TD>Oxford</TD>
<TD>Andrew Protheroe</TD>
</TR>
<TR><TD>London</TD>
<TD>Chris Parker</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10421_1_J%26J%20Marketing%20Campaign.jpg"> </div><div>Source: Elsevier </div><!-- Comment details --><a name="oncology10421attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10421_1_J%26J%20Marketing%20Campaign.jpg">J&J Marketing Campaign.jpg</a>&nbsp;&nbsp;(118,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10421">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-22T17:35:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-22T17:35:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ' Lynparza (olaparib) Shows Promise in Prostate Cancer</title>
	<pubDate>2015-04-22T16:23:25+02:00</pubDate>
	<wp:post_id>6216</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: De Bono presented data to the AACR conference showing that 16 out of 49 men with treatment-resistant, advanced prostate cancer responded to olaparib.<wbr> Among the responders, 14 of the men had detectable DNA repair mutations.<wbr> </div><div style="margin-bottom: 10px;">On the back of the results, the researchers plan to start a second part of the trial in which only men with detectable DNA repair mutations will receive olaparib, in the expectation that the response rate in this group will be much higher.<wbr> </div><div>Olaparib works by blocking an enzyme involved in cell repair and is approved for women with ovarian cancer and hereditary BRCA gene mutations.<wbr> The new research suggests it could also benefit men with genomic faults within their prostate tumors.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10419">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-22T16:23:25+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-22T16:23:25+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Initial Toxin Feedback From The AAN Meeting In Washington DC</title>
	<pubDate>2015-04-22T15:51:17+02:00</pubDate>
	<wp:post_id>6217</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Having been noticeable for their lack of presence at 
Toxins and IMCAS, Allergan has made a major comeback at the AAN 
meeting this week.<wbr> The key emphasis of its booth is on its 
expanded indication in Upper Limb Spasticity &amp; the expansion of the maximum 
dose for such patients.<wbr> Another prominent Company message was its 
stated intention to enhance activites in eye care, CNS, dermatology and 
aesthetics.<wbr> Some initial clinical/<wbr>regulatory comments on some of the 
spasticity trials are also highlighted.<wbr> </div><div style="margin-bottom: 10px;">Coverage of the ANN was outsourced on this occaision to a vendor, hence 
all comments are attributable to the sources with whom they have had 
discussions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Toxin Commerical Presence &amp; Actavis's Commitment To 
Botox</STRONG> </div><div style="margin-bottom: 10px;">The booth some photos of which are shown below included three panels with 
slide shows on each major therapeutic indication, chronic headache, cervical 
dystonia and limb spasticity each with a similar message - "The Botox 
Commitment, Let Botox Be The Next Step For Your xxx Patient".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">The company apparently hosted a not very well publicized reception at a 
nearby restaurant, attended mainly by Allergan employees and a few 
physicians.<wbr>  William Meury EVP of Commercial North American Brands 
from Actavis attended and gave a speech emphasising the importance of Allergan 
and the neurology area for Actavis (including Namzaric - Nameda as well as 
Botox).<wbr> </div><div style="margin-bottom: 10px;">The consensus among Meury and other high ranking executives is that 
Allergan will continue to fund the same level of research for Botox going 
forward.<wbr> It was claimed that the acquisition is not affecting timelines and that 
no changes have been made to the sales force have been made as a result of the 
purchase by Actavis.<wbr> Importantly, Executives do not expect there to 
be any change in sales force numbers </div><div style="margin-bottom: 10px;">Overall most employees seemed to suggest morale is good, staffing changes 
that were going to happen have already happened, (although more layoffs have 
been announced this week in Irvine in unspecified areas) and employees are 
happier with Actavis than they would have been with Valeant.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM><BR>Xeomin (incobotulinumtoxinA) - Merz</EM></STRONG> </div><div style="margin-bottom: 10px;">Key booth messages are: </div><div style="margin-bottom: 10px;"><UL><LI>"Your Art, Xeomin Science" </LI>
<LI>"A Highly Purified Toxin" </LI>
<LI>"Xeomin Science.<wbr>.<wbr>.<wbr>Precision Engineering" </LI>
<LI>"100 years of Merz - a history of innovation"</LI>
</UL> </div><div style="margin-bottom: 10px;">Other messages included in brochure and emphasized by reps - head to heads 
against Botox in cervical dystonia and blepharospasm showed Xeomin not inferior, 
ease of reconstitution and dilution, and multiple vial options to reduce 
cost: smaller vial available, cost $100 less than comparative Botox 
vial.<wbr> </div><div style="margin-bottom: 10px;">The  "doctors grew up with 
Botox" </div><div style="margin-bottom: 10px;">The VA (Veterans Administration) is a key Xeomin user, also 
large hospitals such as Georgetown and Mt.<wbr> Sinai.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>Myobloc (rimabotulinumtoxinB) - Solstice 
Neurosciences</EM></STRONG> </div><div style="margin-bottom: 10px;">Booth messages: </div><div style="margin-bottom: 10px;"><UL><LI>Relieves symptom severity and neck pain from cervical dystonia</LI>
<LI>A unique mechanism of action</LI>
<LI> Effective 1st line treatment for CD patients with 
  pain as a predominant complaint</LI>
</UL> </div><div style="margin-bottom: 10px;">Solstice has 32 reps in the US, a handful of Medical Affairs 
personnel and has grown since its acquisition by USWorldwide 
Meds </div><div style="margin-bottom: 10px;"><STRONG>Clinical Feedback Allergan</STRONG> </div><div style="margin-bottom: 10px;">An Allergan Medical Director claimed that Allergan is in discussions with the 
FDA regarding its ALL filing.<wbr> He also noted that its PUL study is ongoing but 
recruiting slowly, as it is hard to find patients to participate in a 
placebo-controlled trial when agents are already being used.<wbr> </div><div style="margin-bottom: 10px;">Clinical staff claimed that Actavis seems committed to neurological 
indications and hasn't reduced budgets , but of course it is still early 
days.<wbr> The company has not decided what it is going to do with Medytox; it is in 
development but "a ways away" </div><div style="margin-bottom: 10px;">A poster showed 1-year results of the COMPEL trial, a two year phase IV open 
label study of 713 patients with chronic headache.<wbr> The interim results were 
similar to that obtained in the PREEMPT PhIII trial.<wbr> The study will complete at 
the end of 2015 and adds two additional depression measures that PREEMPT did not 
include </div><div style="margin-bottom: 10px;">Allergan sponsored a retrospective analysis (AMEND study) on prophylactic 
treatment patterns by migraine diagnosis showing that chronic headache is 
underdiagnosed </div><div style="margin-bottom: 10px;"><DIV>
<UL><LI>Medical records of 3 neurological practices over a 15 month period 
  including 6,050 patients were reviewed</LI>
<LI>Not much difference was observed between patients classified as 
  chronic headache and non-chronic - mean 22 vs.<wbr> 19.<wbr>2 headache days</LI>
<LI>At first visit, 3% of non-chronic and 41% of chronic patients were using 
  Botox prophylaticly; persistence in both groups was high</LI>
</UL>
<DIV>Allergan staff commented that no action - e.<wbr>g.<wbr> education, outreach, etc.<wbr> 
has been taken yet on this data but it is being considered</DIV>

<DIV>NB.<wbr> Slides from Allergan's platform presentation on its ALL results should 
be avialable tomorrow.<wbr></DIV></DIV> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Feedback Merz </STRONG> </div><div style="margin-bottom: 10px;">Merz Medical Director claimed that Merz have already filed for AUL in the US 
earlier this year, and hope to be approved by the end of the year or by early 
next year.<wbr> They intend to file additional data in supplementary filings </div><div style="margin-bottom: 10px;">Two-cycle data on Xeomin  from the XCiDaBLE trial in the cervical 
dystonia cohort supported what had been shown in pivotal trials, that Xeomin 
resulted in significant improvements in both disease severity and effects on 
employment/<wbr>productivity and mental and physical QOL, with mainly mild 
AEs.<wbr> The trial included 369 subjects with cervical dystonia.<wbr> </div><div>Source: Day 2 &amp; 3 AAN Congress </div><!-- Comment details --><a name="neurology7985attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(90,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(93 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(83,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(100,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(105,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(110,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(96 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(110,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7985_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(102,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7985">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-22T15:51:17+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-22T15:51:17+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas and Potenza Therapeutics Ink Agreement to Build Immuno-Oncology Portfolio</title>
	<pubDate>2015-04-22T15:29:10+02:00</pubDate>
	<wp:post_id>6218</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
<LI>
</LI>
<LI>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- founded in 2014 </div><div style="margin-bottom: 10px;">- offices and laboratories located in Cambridge, MA </div><div style="margin-bottom: 10px;">-  </div><div style="margin-bottom: 10px;"><UL><LI></LI>
</UL> </div><div>Sources: Potenza; Astellas </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10417">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-22T15:29:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-22T15:29:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alimentary Health Shorlisted as a Finalist for its Global Innovation with BIFORTIS</title>
	<pubDate>2015-04-21T18:17:03+02:00</pubDate>
	<wp:post_id>6219</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alimentary Health has been selected as a finalist in the 2015 "The US-Ireland Research Innovation Awards".<wbr>  These prestigious awards recognise excellence and showcase the very best in research innovation in Ireland as a result of US foreign direct investment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Global innovation with Bifidobacterium infantis (B.<wbr> infantis) 35624 or BIFORTIF</STRONG> </div><div style="margin-bottom: 10px;">B.<wbr> infantis 35624 is a specialised patented precision bacterial culture (PrecisionBiotic) developed by Irish and US scientists in Ireland.<wbr> </div><div style="margin-bottom: 10px;">This unique technology, available OTC is sold by Alimentary Health in Ireland as Alflorex&reg;, B.<wbr> infantis 35624 and by Procter &amp; Gamble in North America as Align&reg;.<wbr> </div><div style="margin-bottom: 10px;">Align' is the first successful product launch for P&amp;G in the probiotic category and has already received the &lsquo;Gold Edison Award for Best New Product in 2010&rsquo; in the US.<wbr> </div><div>Furthermore, despite being on the market only 1 year in Ireland, &lsquo;Alflorex&rsquo; was awarded &lsquo;Best Irish Pharmacy Product 2015&rsquo; by Irish Pharmacies See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2287" class="defaultlink">GastroEnterology2287: Alimentary Health's Alflorex Got Strong Endorsement from Irish Pharmacists</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2319">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T18:17:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T18:17:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ICELAND Study Showed Intermittent ADT and Continuous ADT Have Similar Efficacy And Safety Profile</title>
	<pubDate>2015-04-21T17:44:10+02:00</pubDate>
	<wp:post_id>6220</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In the upcoming AUA in 18th May, Dr Claude Schulman (Brussels, Belgium) will be presenting the results of the ICELAND study, funded by Astellas,.<wbr> ICELAND study, a Ph3b study, was a large multi-centre study in EU (n = 933) that aims to increase knowledge regarding the efficacy and safety profile of intermittent (IADT) versus continuous (CADT) androgen deprivation therapy.<wbr> The results showed IADT and CADT showed similar efficacy, tolerability and quality of life.<wbr> In the cohort of patients who initially responded well to 6 months of ADT induction therapy, IADT seems to have been as effective (and safe) as CADT at up to about 5 years of follow-up.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ICELAND Study Design: It is important to note that the key defining factors in this trial are that any patients with metastatic disease are not included.<wbr></STRONG> </div><div style="margin-bottom: 10px;">The ICELAND trial was a large multi-centre study conducted within the European Union.<wbr> It initially enrolled 933 men with with relapsing M0 or locally advanced prostate cancer after radical prostatectomy or radiation therapy.<wbr> All patients also had to have a Gleason score &ge;6, and a life expectancy &ge; 5 years.<wbr> All patients were treated with a 6-month ADT induction regimen of leuprolide acetate 3-month depot 22.<wbr>5 mg + bicalutamide 50 mg/<wbr>day for the first month.<wbr> After this initial 6-month induction therapy, patients with a PSA level of &le; 1 ng/<wbr>ml were randomized 1:1 to either IADT or CADT with leuprolide acetate alone for another 36 months.<wbr> The primary study endpoint was time to PSA progression (i.<wbr>e.<wbr>, three consecutive increasing PSA values, all &ge; 4 ng/<wbr>ml and &ge; 2 weeks apart).<wbr> Patients were subsequently followed at 6-month intervals for a further 18 months to assess overall survival (OS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Patient Characteristic: </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>701 of the original 933 patients had a PSA level of &le; 1 ng/<wbr>ml after the initial induction regimen and were randomized to either IADT or CADT.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>408/<wbr>701 patients (58 percent) had locally advanced prostate cancer.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>293/<wbr>701 patients (42 percent) had relapsing M0 prostate cancer.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The CADT and IADT groups were comparable at baseline.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The average (median) number of injections of leuprolide acetate administered during the 36-month randomized treatment phase was
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>12 in the CADT group (range, 1 to 12)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>3 in the IADT group (range 1 to 10)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings:</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI><STRONG>Time to PSA progression was not significantly different between the two groups: </STRONG>Estimated 3-year PSA progression rates were 10.<wbr>6 percent in the CADT group 10.<wbr>1 percent in the IADT group
</LI>
<LI><STRONG>There were no statistically significant differences between the two groups for PSA progression-free survival, </STRONG>Average (mean) PSA levels over time, Quality of life, and Overall survival.<wbr>
<BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
 </div><div style="margin-bottom: 10px;"><P>=&gt; Estimated 5-year overall survival rates were :85.0 % in the CADT group versus 81.<wbr>8 % in the IADT group</P>
 </div><div style="margin-bottom: 10px;"><P>=&gt; 330/<wbr>352 patients (93.<wbr>8 percent) in the CADT group maintained testosterone levels &lt; 50 ng/<wbr>dl throughout treatment.<wbr></P>
</BLOCKQUOTE>

</LI>
<LI>Most adverse events were mild or moderate: The most common adverse events were
</LI>
</OL> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;">Hot flushes (19 percent in the CADT group vs.<wbr> 21 percent in the IADT group)</P> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;">Hypertension (13 percent in the CADT group vs.<wbr> 11 percent in the IADT group)</P> </div><div style="margin-bottom: 10px;">Schulman et al.<wbr> finally concluded that IADT &ldquo;may be a valid option&rdquo; for selected patients with locally advanced or relapsing M0 prostate cancer although the impact of prior therapies (such as radiation, surgery, or both surgery and radiation) haven't been taken into consideration.<wbr> </div><div style="margin-bottom: 10px;">Source: AUA 2015 (Abstract MP73-20) </div><div>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10413">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T17:44:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T17:44:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OAB: Who is in Control? A Patient-Centric Approach</title>
	<pubDate>2015-04-21T16:59:26+02:00</pubDate>
	<wp:post_id>6221</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; color: #1f497d; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_9_ScreenCapture9.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_10_ScreenCapture10.jpg"> </div><!-- Comment details --><a name="neurology7982attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(72,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(71,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(65,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(95,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(88,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(105,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(101,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7982_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(62,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7982">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T16:59:26+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T16:59:26+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cracking The Code of Refractory OAB: When, Who and How?</title>
	<pubDate>2015-04-21T16:38:24+02:00</pubDate>
	<wp:post_id>6222</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="neurology7980attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(42 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7980_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(43,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7980">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T16:38:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T16:38:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>An Emerging Diagnostic Test In Bladder Cancer</title>
	<pubDate>2015-04-21T12:55:52+02:00</pubDate>
	<wp:post_id>6223</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OncoCyte presented the results from two prospective clinical studies of PanC-Dx&trade; (a non-invasive cancer diagnostic test) that demonstrate high level of sensitivity and specificity in detection of bladder cancer.<wbr> PAnC-Dx&trade; is a urine cytology diagnostic test.<wbr> Joseph Wagner (OncoCyte CEO) believed that the encouraging results to date validate the technology to be used as an alternative to detect bladder cancer or its recurrence compared to currently used costly and invasive diagnostic procedures.<wbr> </div><div style="margin-bottom: 10px;">BioTimes /<wbr>OncoCyte believed that PanC-Dx&trade; in bladder cancer represents a potential of market size of $500 million.<wbr> The results from two prospective clinical studies of <EM>PanC-Dx&trade; </EM>were presented at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 1:00 PM - 5:00 PM EDT on Sunday, April 19, 2015.<wbr> The second bladder cancer clinical trial of up to 1,400 patient samples is half way complete in terms of patient enrolment and results are expected by the end of 2015.<wbr> </div><div style="margin-bottom: 10px;">The first clinical study was conducted by OncoCyte in collaboration with investigators in the Department of Pathology at Johns Hopkins University School of Medicine led by Matthew T.<wbr> Olson, M.<wbr>D.<wbr>(principal investigator) and Professor Dorothy Rosenthal, M.<wbr>D.<wbr>, (collaborator on the study).<wbr> Investigators in the trial are collecting urine samples from patients undergoing cystoscopy for the diagnosis of either primary or recurrent bladder cancer.<wbr> A gene expression classifier was developed with the goal of distinguishing between UC and benign conditions.<wbr> Performance of the classifier was evaluated using several cross-validation criteria, including Receiver Operating Characteristic (ROC) area under the curve (AUC) analysis, yielding an AUC of 0.<wbr>91 (sensitivity of 90% with a specificity of 82.<wbr>5%).<wbr> Optimal performance of the classifier was achieved using only two markers.<wbr> </div><div style="margin-bottom: 10px;">The second clinical trial is underway with the objective of 1,400 patient samples included and the study is expected to complete by end of 2015.<wbr> This study will further validate the commercialisation value of the diagnostic test although FDA approval would necessitate additional pivotal clinical studies.<wbr> </div><div>Source: BioTime Press Release, AACR 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10412">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T12:55:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T12:55:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: A New Class Of Targeted Therapy - CDK4 /6 Inhibitor - Emerges For HER2- ER+ Breast Cancer</title>
	<pubDate>2015-04-21T12:01:12+02:00</pubDate>
	<wp:post_id>6224</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">A New Class Of Targeted Therapy - CDK4 /<wbr>6 Inhibitor - Emerges For HER2- ER+ Breast Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: Pfizer announced FDA acceptance of palbociclib (a CDK4/<wbr>6 inhibitor) new drug application (NDA) with priority review.<wbr> This NDA requests FDA approval of palbociclib in combination with letrozole as a 1L treatment for postmenopausal women with oestrogen receptor positive, and HER2- advanced breast cancer.<wbr> This acceleration allows shortening of 4 months approval timeline.<wbr> Pfizer first received breakthrough therapy designation from the FDA in April 2013.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10037">...</a><br></div><div>Novartis has recently listed a new clinical trial for LEE011 in Neuroendocrine Tumors of Foregut Origin (<a href="https://clinicaltrials.gov/ct2/show/NCT02420691?term=LEE011&rank=3&submit_fld_opt=" class="defaultlink">NCT02420691</a>).<wbr> The Phase II trial, not yet open for participant recruitment, is sponsored by the M.<wbr>D.<wbr> Anderson cancer Center in collaboration with Novartis and is designed to learn if LEE011, a novel CDK 4/<wbr>6 inhibitor, could play a role in controlling advanced neuroendocrine tumors of the foregut.<wbr> The safety of the drug will also be assessed during the trial that is supposed to start in July 2015, with estimated primary completion date due in July 2018.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8029">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10037">View thread  Oncology10037: A New Class Of Targeted Therapy - CDK4 /<wbr>6 Inhibitor - Emerges For HER2- ER+ Breast Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T12:01:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T12:01:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Poster Presented @ AACR Supports Galeterone Potential Beyond Prostate Cancer</title>
	<pubDate>2015-04-21T11:10:14+02:00</pubDate>
	<wp:post_id>6225</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Scientists in the laboratory of Vincent Njar, PhD, at the U.<wbr> of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and migration of human pancreatic ductal adenocarcinoma (PDAC) cells.<wbr> These results also demonstrate the potential of Tokai's ARDA platform.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster Presentation</STRONG> </div><div style="margin-bottom: 10px;">Poster presentation titled, &ldquo;Galeterone and Its Novel Analogs Induce Profound Anti-Cancer Activities in Human Pancreatic Cancer Cell Lines,&rdquo; abstract number 1764.<wbr> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="text-decoration: underline;">From BMO Capital Market:</SPAN></P> </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="7" cellspacing="0" dir="ltr" style="width: 461px;"><TBODY><TR><TD height="111" valign="top">
<P align="justify"></P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG>ARDA Platform</STRONG> </div><div>ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10409">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T11:10:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T11:10:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' PI3K Inhibitor + Letrozole Showed Early Signs Of Activitiy In ER+ Metastatic Breast Cancer</title>
	<pubDate>2015-04-21T11:06:55+02:00</pubDate>
	<wp:post_id>6226</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Ingrid Mayer (Vanderbilt-Ingram Cancer Center, Tennessee) presented at AACR the data from a Phase Ib trial (<a href="https://clinicaltrials.gov/ct2/show/NCT01791478?term=NCT01791478&rank=1" class="defaultlink">NCT01791478)</a> that demonstrate some ER+ patients that are no longer responding to anti-oestrogen therapies had relatively long lasting clinical benefit from combination therapy with alpelisib (PI3K inhibitor, Novartis) and letrozole (anti-oestrogen).<wbr> Based on the data, Dr Meyer indicated a PhIII clinical trial will soon start global accrual.<wbr> </div><div style="margin-bottom: 10px;">Anti-oestrogen therapies like tamoxifen and letrozole are the standard of care for patients with ER-positive breast cancer.<wbr> Is cancer eventually becomes resistant to these treatments and their disease progresses.<wbr> Preclinical studies have shown that ER-positive breast cancer cells frequently use the PI3K signalling pathway to circumvent the anticancer effects of an anti-oestrogen therapy and that adding a PI3K inhibitor to an anti-oestrogen therapy seems to restore the sensitivity of ER-positive breast cancer cells to anti-oestrogen therapies.<wbr> This provided the basis for exploring further with combination approach.<wbr> </div><div style="margin-bottom: 10px;">The latest analysis of the data showed that some patients with ER-positive breast cancer that is no longer responding to anti-oestrogen therapies had relatively long-lasting clinical benefit (i.<wbr>e.<wbr>, lack of disease progression): the longest duration on treatment was 20 months, but several other patients remained on study for over 14 months without disease progression.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>19% of patients on the study had a partial response ( five patients experienced a partial response, two of whom are still on treatment)
</LI>
<LI>43% of patients had stable disease;
</LI>
<LI>35% of patients had clinical benefit for over six months;
</LI>
<LI>30% of patients had clinical benefit for over 12 months,&rdquo;
</LI>
</UL> </div><div style="margin-bottom: 10px;">This study was funded by Stand Up To Cancer, Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence (SPORE) from the National Cancer Institute, and Novartis.<wbr> Dr.<wbr> Mayer receives research support from Novartis.<wbr> </div><div>Source: AACR 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10407">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T11:06:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T11:06:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</title>
	<pubDate>2015-04-21T11:00:08+02:00</pubDate>
	<wp:post_id>6227</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Belgium based, private company presented at ENDO2013 preclinical PK and efficacy data of its oral small-molecule NK3 receptor antagonist program.<wbr> ESN364, the lead candidate issued from this program, is scheduled for FIM in 4Q:13 (endometriosis and polycystic ovary syndrome).<wbr> Of note, the company is actively seeking partner for ESN282 (inflammatory diseases such as ulcerative colitis).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=9023">...</a><br></div><div>Euroscreen has initiated two POC trials in UF (Uterine fibroids) and PCOS (Polycystic ovary syndrome).<wbr> The launch of these trials builds upon the efficacy data established in Ph1 wherein ESN364 lowered plasma levels of estrogen and progesterone as a result of its selective effect on pulsatile LH secretion.<wbr> The demonstrated selective modulation of gonadotropins mitigates the risk of the induction of menopausal-like adverse events, such as loss of bone mineral density and the induction of hot flashes.<wbr> Thus, in contrast to the existing GnRH products, the non-castrating drug profile of ESN364 presents an opportunity for chronic dosing without any need for add-back therapy for the chronic treatment of Women&rsquo;s Health Disorders.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10406">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023">View thread  Oncology9023: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-21T11:00:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-21T11:00:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Negative Reimbursement Decisions for Rotavirus Vaccines in France</title>
	<pubDate>2015-04-20T17:29:03+02:00</pubDate>
	<wp:post_id>6228</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Rotateq has not been recommended by the Transparency Commission (TC) for its inclusion in the national reimbursement list.<wbr> Rotarix has been rejected for reimbursement approval (the TC has considered that its actual benefit is insufficient).<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Sanofi Pasteur (France) and Merck &amp; Co (US)'s rotavirus vaccine RotaTeq has not been recommended by the TC for its inclusion in the national reimbursement list.<wbr> The drug received an "insufficient" clinical value rating (SMR) for the active immunisation of infants from the age of six weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG>
</P> </div><div style="margin-bottom: 10px;">GlaxoSmithKline (GSK; UK)'s rotavirus vaccine Rotarix has been rejected for reimbursement approval.<wbr> In particular, the TC has considered that the actual benefit of Rotarix is insufficient for the reimbursement of the medicine for the active immunisation of infants from the age of six weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection.<wbr>
 </div><div><P class="bodyHeading2">Source: from IHS GlobalInsight</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150431&edate=20150401&rec=2318">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-20T17:29:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-20T17:29:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Expanded AUL Label For Botox In The US.</title>
	<pubDate>2015-04-20T16:25:13+02:00</pubDate>
	<wp:post_id>6229</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Actavis has announced today an expansion of its US label for Botox 
for the treatment of adults with upper limb spasticity.<wbr> The expanded label now 
includes the addition of two thumb muscles: a muscle in the forearm that 
flexes the thumb and one in the hand that adductx the thumb, plus an 
increase in overall maximum dose for treating upper limb spasticity from 360U to 
400U.<wbr> </div><div style="margin-bottom: 10px;">This FDA approval expands Botox's previous label approved in 2010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Expanded Label Based On Two Additional Trials</STRONG> </div><div style="margin-bottom: 10px;">This expanded label approval for the two thumb flexor muscles is based on two 
additional randomized, multi-center, double-blind, placebo-controlled studies 
evaluating the efficacy and safety of BOTOX® in patients with upper limb 
spasticity.<wbr> </div><div style="margin-bottom: 10px;">In the first study, the efficacy and safety of one-time BOTOX® injections in 
170 patients with upper limb spasticity were evaluated.<wbr> Patients received a 
single treatment of BOTOX® (40 units) or placebo into thumb flexor muscles.<wbr> This 
study investigated the median change from baseline to week 6 in thumb flexor 
tone measured by the modified Ashworth Scale.<wbr> Results showed that BOTOX® 
neurotoxin produced a clinically and statistically significant reduction of 1.<wbr>0 
BOTOX® vs 0.<wbr>0 placebo (p&lt; 0.<wbr>001).<wbr> </div><div>The second trial evaluated the efficacy and safety of one-time BOTOX® 
injections in 109 patients with upper limb spasticity.<wbr> Patients received a 
single treatment with lower dose (30 units) or higher dose (40 units) of BOTOX® 
or placebo into thumb flexor muscles.<wbr> The study found that the higher dose of 
BOTOX® produced a clinically and statistically significant reduction in thumb 
flexor muscle tone on the modified Ashworth Scale of 0.<wbr>5 BOTOX® vs 0.<wbr>0 placebo 
(p&lt; 0.<wbr>010).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7966">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-20T16:25:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-20T16:25:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Menarini and 4SC Ink Reminostat Deal for Asia</title>
	<pubDate>2015-04-20T13:54:33+02:00</pubDate>
	<wp:post_id>6230</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Menarini will receive the exclusive licensing rights for the development and marketing of resminostat, an oral histone-deacetylase, in all APAC countries (including among others China, South Korea, Australia, Thailand, Philippines, Indonesia, and Vietnam).<wbr> 4SC will receive upfront and milestone payments totaling approx up to €95M ($100.<wbr>5M) from Menarini payable upon achieving specified development, regulatory and commercialization milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">4 years ago 4SC received an upfront payment from Yakult Honsha of €6M and up to €127M payable upon achieving specified milestones including clinical and regulatory events in Japan </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Menarini Asia-Pacific operates across the entire commercial value chain from clinical development regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields including Consumer Health Dermatology Primary Care Allergy/<wbr>Respiratory Cardiovascular Oncology/<wbr>Specialty Care and Men’s Health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Dev Programs</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10404_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Mechanism of Action</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10404_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology10404attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10404_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10404_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(113,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10404">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-20T13:54:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-20T13:54:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progenics - An Interesting Company with both Endocrinology and Oncology Development Programmes</title>
	<pubDate>2015-04-17T19:34:18+02:00</pubDate>
	<wp:post_id>6231</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Progenics presentation at the Needham H.<wbr>C Confernece highlighted the effectiveness of its phaechormacytoma drug Azedra which Progenics acquired throught the purchase of Molecular Insight and the intriguingly dramatic early efficacy being seen with the group's PSMA molecules (ADC and radiopharmaceutical) under development for advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Prog Plan to commercialise Azedra itself as only a small sales force is required to cover the 12-15 centres that treat phaechromacytoma in the US.<wbr> Progenics considers Azedra to be a de-risked programme with agreement that continued development can be undertaken under an SPA.<wbr> The company just needs to show now that the drug performs as well in its hands as it did whilst Molecular Insight was running the trial before it went bankrupt </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_2_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Progenics CEO noted that when he had showed this dat to KOLs and asked their views they were impressed with the survival seen.<wbr> He claimed to have received very strong feedback that the drug will provide a very strong benefit for these patients.<wbr> </div><div style="margin-bottom: 10px;">Progenics prostate pipeline includes one radiopharmaceutical imaging agent and two therapeutics all of which target PSMA.<wbr> The excitement surrounding the PSMA approach to imaging and treatment of prostate cancer was highlighted at the recent 3rd World Congress on Ga-68 and radiopeptide therapy (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8025" class="defaultlink">Endocrinology8025: Key Learnings From the 3rd World Theranostic Congress on Ga-68 & RadiopeptideTherapy</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_7_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Accuracy of the imaging agent has had to be compared with results of prostatectomy as part of requirements from the FDA.<wbr> This has limited where in prostate cancer trials to date have been conducted but it is believed that the opportunity can ultimately be much broader than this.<wbr> Progenics highlighted the dramatic difference between what can be observed with and MRI scan compared to that with 1404.<wbr> Created a more accurate test that is easier for patients and clinicians to understand.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Two Prostate Therapeutics</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_9_ScreenCapture10.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_10_ScreenCapture11.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_11_ScreenCapture12.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_12_ScreenCapture13.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_14_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_15_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_16_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_17_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_18_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_19_ScreenCapture20.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_20_ScreenCapture21.jpg"> </div><!-- Comment details --><a name="oncology10400attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(88,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(95,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(74,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(66 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(84 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(78,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(71,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(69,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(73,9 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(72,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(69,4 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_15_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(63,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_16_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(106,6 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_17_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(79,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_18_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(82,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_19_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(108,9 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10400_20_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(67 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10400">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T19:34:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T19:34:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Q-Octreotide To Move Into Clinical Development In 2016</title>
	<pubDate>2015-04-17T18:57:09+02:00</pubDate>
	<wp:post_id>6232</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During its Q4 earnings call today, Midatech noted that it is 
fast-tracking two of Q-Chip's lead products including Q-Octreotide a long-acting 
formulation of octreotide.<wbr> Currently in preclinical development the group hopes 
to move the product into clinical development next year.<wbr> The product is being 
developed for out-licensing purposes </div><div style="margin-bottom: 10px;">Midatech do not want to market Q-octreotide themselves but consider that the 
product will add value to the business in the future.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Midatech's Key Operational Highlights 2014 </STRONG><STRONG>·</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
  Awarded a €7.<wbr>9m Horizon 2020 European 
  Union grant (€3.<wbr>4m direct to the Group) to fund manufacturing scale-up - 
  September 2014</LI>
<LI>
  Acquisition of Q Chip Limited ("Q Chip") bringing complementary 
  technology and products, enabling sustained release over extended periods of 
  time - December 2014</LI>
<LI>
  Positive results achieved in proof-of-concept OpsiSporin study 
  with sustained release treatment for uveitis (ocular inflammation) - February 
  2015</LI>
<LI>
  Research collaboration agreement signed with unnamed global 
  pharmaceutical company in field of diabetes - March 2015</LI>
<LI>
  Appointment of Nick Robbins-Cherry, Finance Director in February 
  2014 and Dr Craig Cook, Chief Operating Officer in January 2014</LI>
<LI>
  Research collaboration agreement signed with Dana-Farber Cancer 
  Institute covering a nanoparticle formulation for the treatment of 
  Glioblastoma - April 2015</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="mc">Financial Highlights</P> </div><div style="margin-bottom: 10px;"><UL><LI>
  Oversubscribed flotation on the AIM market of the London Stock 
  Exchange in December 2014 raising £32.<wbr>0m (before expenses)</LI>
<LI>
  Combined proforma revenue ahead of expectations at 
  £0.<wbr>73m</LI>
<LI>
  Strong balance sheet with £30.<wbr>33m cash and deposits at 31 
  December 2014 (2013: £2.<wbr>39m)</LI>
<LI>
  Net loss after tax of £7.<wbr>38m (2013: £4.<wbr>08m) with net cash inflow 
  in the year of £27.<wbr>94m (2013: £2.<wbr>25m)</LI>
<LI>
  Tax credit receivable of £0.<wbr>84m (2013: £0.<wbr>80m)</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Courier New'; COLOR: black; mso-fareast-font-family: 'Courier New'"><SPAN style="mso-list: Ignore">    
</SPAN></SPAN><I><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial',sans-serif; COLOR: black">Considered 
an early identifiable liciensing product, not wanting to take it market 
themselves <U9:P></U9:P></SPAN></I> </div><div><SPAN lang="EN-US" style="FONT-FAMILY: 'Courier New'; COLOR: black; mso-fareast-font-family: 'Courier New'"><SPAN style="mso-list: Ignore">    
</SPAN></SPAN><SPAN lang="EN-US" style="FONT-FAMILY: 'Courier New'; COLOR: black; mso-fareast-font-family: 'Courier New'"><SPAN style="mso-list: Ignore">    
</SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150431&edate=20150401&rec=8028">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T18:57:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T18:57:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US Generic Association Launches Biosimilars Council to Promote Access to Biosimilar Drugs</title>
	<pubDate>2015-04-17T18:02:34+02:00</pubDate>
	<wp:post_id>6233</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P class="documentTitle">Comment: GPhA has launched a Biosimilars Council division within the association, comprising drug manufacturers and other stakeholders that will strive towards achieving a favourable regulatory, reimbursement, political, and policy environment for biosimilars' access in the US.<wbr> The Biosimilars Council will elect a board that will lead the association's biosimilar activities.<wbr> In addition to advocacy, the council will also provide educational resources to the general public and patients regarding the safety and efficacy of biosimilars, including the new handbook titled "The Next Frontier for Improved Access to Medicines: Biosimilars and Interchangeable Biologic Products".<wbr></P> </div><div style="margin-bottom: 10px;"><P class="documentTitle"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="documentTitle">The GPhA's Biosimilars Council will help lay the ground work for the first set of biosimilar drugs that are making their way onto the US market, highlighting their safety, the legal and regulatory framework set in place for their review, and their affordability compared with branded biologic therapies.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="documentTitle">The US FDA approved the first official biosimilar drug, Zarxio (filgrastim-sndz; Novartis, Switzerland), in March 2015, although the drug has yet to be launched on the market due to ongoing litigation with Amgen </P> </div><div style="margin-bottom: 10px;"><P class="documentTitle">An uptake of biosimilars in the US will probably be aided substantially by promotional, educational, and lobbying by the association.<wbr> Craig Wheeler, the CEO of Momenta Pharmaceuticals (US) and chair of the GPhA board, "The GPhA Biosimilars Council is designed to meet the unique needs of healthcare companies as they navigate this emerging space.<wbr>"</P> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11151_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Link: <A href="http://www.biosimilarscouncil.org/pdf/GPhA-biosimilars-handbook.pdf">http:/<wbr>/<wbr>www.<wbr>biosimilarscouncil.<wbr>org/<wbr>pdf/<wbr>GPhA-biosimilars-handbook.<wbr>pdf</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11151_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11151_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld11151attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11151_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11151_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11151_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(28,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150431&edate=20150401&rec=11151">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T18:02:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T18:02:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz to Present New Data @ AAN</title>
	<pubDate>2015-04-17T17:31:30+02:00</pubDate>
	<wp:post_id>6234</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Posters will present 'important real-world disease stat information' from the Cervical Dystonia and Blepharospasm cohorts of the XCiDaBLE trial.<wbr> Another poster will present 'structured interview evalating botulinum toxin type A for blepharospasm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7965_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.ncbi.nlm.nih.gov/pubmed/25120942">Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm</A> </div><div><A href="http://www.ncbi.nlm.nih.gov/pubmed/23724362">Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia</A> </div><!-- Comment details --><a name="neurology7965attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7965_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(139,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150431&edate=20150401&rec=7965">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T17:31:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T17:31:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TOKAI Presented The Progress Of ARMOR-3 For Galeterone At The 14th Annual Needham Healthcare Conference</title>
	<pubDate>2015-04-17T16:58:01+02:00</pubDate>
	<wp:post_id>6235</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On Tuesday shares of Tokai Pharmaceuticals, Inc.<wbr> closed at $12.<wbr>72 following announcement of the appointment of Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc.<wbr>, to its Board of Directors.<wbr> Lee Kalowski, Chief Financial Officer, presented at the 14th Annual Needham Healthcare Conference in New York on Wednesday, 15th April to provide update on progress of the current Ph3 trial planned for galeterone in prostate cancer and future company strategic focus.<wbr> </div><div style="margin-bottom: 10px;">Below are the key takeaways from the presentation: </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Progress on ARMOR-3:</STRONG> expected to enroll a total of 148 patients (already pre-agreed with FDA) who harbour ARV7 splice variant.<wbr> Preliminary data suggested 14-26% abiraterone or enzalutamide naive CRPC patients habouring ARV7 variant.<wbr>.<wbr> The Ph3 trial design is to enroll M1 chemo naive pateints who are also abiraterone or enzalutamide naive with a 1:1 randomization into one of the two arms of galeterone versus enzalutamide.<wbr> The main inclusion crtieria are patients with ECOG performance status 1-2 and a detectable ARV7 variant by the companion test developed by Qiagen.<wbr> This companion test will be included in the Ph3 trial, and will be part of the registration label.<wbr> The validation of the companion test is expected to complete this quarter (Q2 2015) and ready to start enrolling patients into the Ph3 trial.<wbr>
</LI>
<LI><STRONG>Commercialisation Readiness:</STRONG> Tokai indicated that they have multiple vendors awaiting for finalised manufacture plan.<wbr> In terms of financial, Tokai has sufficeint funding to allow the company to solely run the Ph3 trial into 2017 when topline results will be availalble.<wbr> Lee Kalwoski believed this will allow TOKAI to find a <EM><STRONG>powerful</STRONG></EM> partner fo commercialise galeterone.<wbr>
</LI>
<LI>Galeterone's IP protection is until 2026 for ex-US and 2027 for US
</LI>
<LI>Future indications will be explored include pancreatic cancer (pre-clinical data will be presented at AACR 2015) and breast cancer (although the role of ARV7 in breast cancer has yet to be defined), Other combination approach may be considered in bladder and uterine cancer.<wbr>
</LI>
<LI>Long Term pipeline extension: utilising existing platofrm to identify second generation of AR degradation candidate
</LI>
</UL> </div><div>Source: Tokai Webcast </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10398">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T16:58:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T16:58:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Debiopharm to Showcase Results of Two Onco Programs @ AACR</title>
	<pubDate>2015-04-17T13:13:47+02:00</pubDate>
	<wp:post_id>6236</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Preclinical data on Debio 1143 (SMAC mimetic) and Debio 1347/<wbr>CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported that " .<wbr>.<wbr>.<wbr> Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers".<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10397_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology10397attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10397_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(112,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150431&edate=20150401&rec=10397">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T13:13:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T13:13:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Clinical, Regulatory, Business Challenges and Rewards of Orphan Development and Approval — EU and International</title>
	<pubDate>2015-04-17T11:44:22+02:00</pubDate>
	<wp:post_id>6237</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><V:STROKE><V:PATH><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png“,”"></V:IMAGEDATA><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image002.png“,”"></V:IMAGEDATA></V:PATH></V:STROKE> </div><div style="margin-bottom: 10px;"><V:STROKE><V:PATH><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png“,”"></V:IMAGEDATA><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image002.png“,”"></V:IMAGEDATA></V:PATH></V:STROKE> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="pharmaworld11145attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(651 B)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(87,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(68,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(51,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(91,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(63,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(74,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150431&edate=20150401&rec=11145">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T11:44:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T11:44:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Clinical, Regulatory, Business Challenges and Rewards of Orphan Development and Approval — EU and International</title>
	<pubDate>2015-04-17T11:44:22+02:00</pubDate>
	<wp:post_id>6237</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><V:STROKE><V:PATH><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png“,”"></V:IMAGEDATA><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image002.png“,”"></V:IMAGEDATA></V:PATH></V:STROKE> </div><div style="margin-bottom: 10px;"><V:STROKE><V:PATH><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png“,”"></V:IMAGEDATA><V:IMAGEDATA src="“,”file:///C:\Users\amh53304\AppData\Local\Temp\msohtmlclip1\01\clip_image002.png“,”"></V:IMAGEDATA></V:PATH></V:STROKE> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="pharmaworld11145attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(651 B)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(87,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(68,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(51,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(91,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(63,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11145_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(74,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150431&edate=20150401&rec=11145">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-04-17T11:44:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-04-17T11:44:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
